XERS Operating Cash Flow
$56.61MTTM · USD
Period ending:
XERS FY Operating Cash FlowUSD
$28.63M-$102.89M
2016-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
XERS operating cash flow history
Cash generated from core business operations. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.
| Period ending | Operating Cash Flow (USD) |
|---|---|
| 28,626,000 | |
| -36,981,000 | |
| -47,023,000 | |
| -102,891,000 | |
| -95,535,000 | |
| -80,558,000 | |
| -80,558,000 | |
| -56,279,000 | |
| -24,663,000 | |
| -16,087,000 |
Compare operating cash flow
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) operating cash flow
- Bridgebio Pharma Inc (BBIO) operating cash flow
- Brightspring Health Services Inc (BTSG) operating cash flow
- Madrigal Pharmaceuticals Inc (MDGL) operating cash flow
- Ensign Group Inc (ENSG) operating cash flow
- Glaukos Corp (GKOS) operating cash flow
- Vaxcyte Inc (PCVX) operating cash flow
- Krystal Biotech Inc (KRYS) operating cash flow
All XERS financial metrics · XERS stock overview · How to interpret financial metrics
